SCHEDULE 13G/A: Benjamin J. Zeskind Discloses 12.8% Beneficial Ownership in Immuneering Corporation
Beneficial Ownership Report
Benjamin J. Zeskind has filed an amended Schedule 13G, reporting a 12.8% beneficial ownership stake in Immuneering Corporation's Class A common stock as of December 31, 2024.
Summary
- Benjamin J. Zeskind, a U.S. citizen, is the Reporting Person for this Schedule 13G Amendment No. 3 filing.
- As of December 31, 2024, Mr. Zeskind beneficially owns an aggregate of 3,978,168 shares of Immuneering Corporation's Class A common stock.
- This ownership represents 12.8% of the Class A common stock outstanding.
- The calculation is based on 31,050,448 shares of Class A Common Stock outstanding as of November 6, 2024, as disclosed in the Issuer's Form 10-Q filed on November 13, 2024.
- Mr. Zeskind holds sole voting and sole dispositive power over 3,083,241 shares.
- He holds shared voting and shared dispositive power over 894,927 shares.
- The beneficial ownership consists of 2,281,852 shares held directly by Mr. Zeskind, 801,389 shares underlying stock options exercisable on or prior to March 1, 2025, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust, where his spouse serves as sole trustee.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership filing (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's operational or financial performance. It is a factual disclosure of an ownership stake.
Positives
- The disclosure of a significant beneficial ownership stake by an individual (likely an insider given the address) can indicate alignment of interests between management/founders and shareholders.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake held by an individual, potentially an insider, which can influence perceptions of corporate control and alignment.
Key Dates
| Date | Description |
|---|---|
| 11/06/2024 | Date as of which 31,050,448 shares of Class A Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 11/13/2024 | Date Immuneering Corporation's Quarterly Report on Form 10-Q was filed with the SEC. |
| 12/31/2024 | Date of event which requires the filing of this statement (reporting period end date). |
| 01/17/2025 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
| 03/01/2025 | Deadline for exercising 801,389 stock options held by Benjamin J. Zeskind. |
Keywords
Immuneering Corporation, Benjamin J. Zeskind, Schedule 13G, Beneficial Ownership, Class A Common Stock, Equity Stake, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.